Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2]. Core Views - The report highlights that the company has transformed into a leading player in the domestic CDMO sector, ranking in the top five of the "Top 20 CDMO Companies in China" for five consecutive years since 2020 [10][12]. - The company aims to expand its CDMO operational projects to 3,000 within 2-3 years, with 10-20 projects entering commercialization annually [10]. - The report emphasizes the company's comprehensive upgrades in both technical investment and manufacturing capabilities, which are expected to drive future growth [80]. Summary by Sections Section 1: Progress in CDMO Sector - The company has accumulated over 20 years of experience and has shifted from a traditional API company to a leading small molecule CDMO provider [10]. - The company has established a solid foundation for CDMO development through its extensive experience in chemical synthesis and production processes [11]. Section 2: R&D Capabilities - The company has significantly increased its R&D investment, expanding its CDMO R&D personnel from over 500 to an expected 1,000 in the next two years [32][41]. - It has established three major R&D centers globally and eight technical platforms to enhance its project acquisition and cost control capabilities [32][42]. Section 3: Manufacturing Advantages - The company maintains a strong manufacturing capability with a total chemical synthesis capacity of 11,000 m³ and a total biological fermentation capacity of 6,570 m³ [63]. - It has received multiple international certifications, including WHO, FDA, and EU EDQM, which enhances its service capabilities for global clients [63]. Section 4: Future Growth Potential - The company has signed confidentiality agreements with 572 domestic and international innovative pharmaceutical companies, indicating strong client engagement [66]. - The report notes that the company has 116 API projects, with 22 already commercialized and 15 in the validation stage, providing a robust growth pipeline [66]. Section 5: Financial Projections - The company is projected to achieve a net profit of 1.0 billion, 1.2 billion, and 1.5 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 17, 14, and 11 [80].

截至7月7日收盘，CRO概念下跌1.07%，位居概念板块跌幅榜前列，板块内，汇宇制药、*ST双成、睿 智医药等跌幅居前，股价上涨的有15只，涨幅居前的有诺思格、昭衍新药、翰宇药业等，分别上涨 3.03%、2.24%、2.11%。 | 002675 | 东诚药业 | -3.15 | 2.11 | -1460.10 | | --- | --- | --- | --- | --- | | 002821 | 凯莱英 | -2.94 | 1.10 | -1440.10 | | 688117 | 圣诺生物 | -0.77 | 7.83 | -1379.21 | | 603229 | 奥翔药业 | -2.05 | 1.37 | -1331.54 | | 300261 | 雅本化学 | -0.14 | 1.47 | -1240.44 | | 300363 | 博腾股份 | -1.98 | 1.86 | -1086.79 | | 301277 | 新天地 | -0.62 | 7.98 | -1072.75 | | 301509 | 金凯生科 | -0.61 | 7.64 | -985.87 | | 603538 | 美诺华 | ...

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, particularly focusing on PD-1/VEGF dual antibodies [1]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 3.64%, outperforming the Shanghai Composite Index (1.54%) and the Wind All A Index (1.22%). The PD-1/VEGF related stocks led the gains, with other biopharmaceuticals rising by 8.28% [2][7]. - A significant partnership was announced between Bristol-Myers Squibb (BMS) and BioNTech, involving a $11.1 billion agreement to co-develop and commercialize BioNTech's PD-L1/VEGF dual-specific antibody BNT327. This highlights the strategic importance of PD-1/VEGF dual antibodies in the global market [2][3]. - The report emphasizes the increasing interest from multinational corporations (MNCs) in the PD-1/VEGF dual antibody space, suggesting that domestic biotech firms are well-positioned for future business development (BD) opportunities [2][3]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector experienced a 3.64% increase, with notable performances from individual stocks such as Seer Medical (51.5%), Guangsheng Tang (48.6%), and Shenzhou Cell-U (45%) [7][10]. - The report notes that the other biopharmaceuticals sector rose by 8.28%, while medical devices and hospitals saw slight declines [2][7]. Industry News and Key Company Announcements - On July 1, the National Healthcare Security Administration released proposals for the adjustment of the 2025 National Basic Medical Insurance drug catalog, aiming to support innovative drug development [12]. - Significant approvals were noted, including the launch of TQG203 for treating hemophilia and the approval of Liraglutide for obstructive sleep apnea [12][13]. - Strategic investments were highlighted, such as Sanofi's investment in Tianyan Pharmaceutical, which will support the development of SAFEbody antibodies [15]. Company Announcements - Several companies reported significant developments, including the approval of new drugs and strategic partnerships aimed at enhancing their market positions [15][16]. - Notably, the report mentions the approval of innovative drugs that address unmet medical needs, indicating a trend towards more targeted therapies in the market [12][13].

Group 1 - The core viewpoint of the article highlights the opportunities for the health consumption sector in China due to the aging population and supportive government policies, as outlined in the "Action Plan for Promoting Healthy Consumption" released by 12 departments including the Ministry of Commerce and the National Health Commission [1] - The discussion at the "European Forum" in Paris emphasized the rapid development of China's medical innovation sector and the unique opportunities for Sino-European cooperation in healthcare, as stated by former French Health Minister Olivier Véran [1][3] - Véran noted that cooperation between China and Europe could lead to both regions becoming long-term partners and global leaders in healthcare, with China needing access to European markets and Europe seeking to deepen connections with Chinese innovation resources [1][3] Group 2 - Olivier Dessajan, CEO of High Life China and President of the French Health Industry Alliance, expressed the importance of collaboration with China, stating that not engaging with China would be a mistake [3] - The establishment of high-end medical service nursing homes in cities like Guangzhou, Hangzhou, and Shenzhen by High Life China reflects the adaptation to local regulations while incorporating French operational mechanisms [3] - The CEO of Pro Pharma, Zhu Fangmeng, emphasized the significance of Sino-European cooperation in innovation and manufacturing, noting that nearly one-third of their overseas market is in Europe [3] Group 3 - The discussion highlighted the advanced technologies available in France and Europe, such as confocal endoscopy and radiofrequency ablation devices, while China leads in AI-assisted treatments and clinical trial results [4] - Véran pointed out the important reforms China has made to facilitate the entry of biopharmaceutical companies into the European market, particularly in modernizing drug regulations and accelerating clinical trials [4] - The strategy for AI application in healthcare should balance caution and innovation to promote harmonious economic relations and public interest between China and Europe, according to Véran [4]

关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江巨泰药 业有限公司收到国家药品监督管理局（以下简称"药监局"）签发的头孢克肟胶 囊《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：头孢克肟胶囊 2、剂型：胶囊剂 3、规格：0.1g（按 C16H15N5O7S2计） 证券代码：000739 证券简称：普洛药业 公告编号：2025-38 普洛药业股份有限公司 8、药品批准文号：国药准字 H20254638 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 本品适用于对头孢克肟敏感的链球菌属（肠球菌除外）、肺炎球菌、淋球菌、 卡他布兰汉球菌、大肠埃希菌、克雷伯杆菌属、沙雷菌属、变形杆菌属及流感嗜 血杆菌等引起的下列细菌感染性疾病：急性支气管炎、肺炎、慢性呼吸系统感染 疾病的继发感染、膀胱炎、肾盂肾炎、淋球菌性尿道炎、胆囊炎、胆管炎、中耳 炎、副鼻窦炎、猩红 ...

Group 1 - The company, Prolog Pharma, announced that its wholly-owned subsidiary, Zhejiang Jutai Pharmaceutical Co., Ltd., received a drug registration certificate for Cefaclor capsules from the National Medical Products Administration [1] - The drug is indicated for bacterial infections caused by Streptococcus and other bacteria sensitive to Cefaclor [1] - The projected market size for the Chinese hospital market in 2024 is 455 million capsules, with a sales value of 387 million yuan [1] Group 2 - As of the announcement date, the total R&D investment for Cefaclor capsules amounted to 6.1 million yuan [1] - Obtaining the registration certificate is equivalent to passing the consistency evaluation of generic drug quality and efficacy, which qualifies the product for subsequent centralized procurement [1] - This development is expected to enhance the company's market competitiveness [1]

公司于2025年4月25日召开第九届董事会第十三次会议审议通过了《关于增 加回购股份资金来源的议案》，同意将本次回购股份的资金来源由"自有资金" 调整为"自有资金及金融机构借款"。除增加回购股份资金来源以外，公司本次 回购股份方案的其他内容未发生变化。具体内容详见公司于2025年4月26日在《证 券时报》和巨潮资讯网（http://www.cninfo.com.cn）上披露的《第九届董事会 第十三次会议决议公告》（公告编号：2025-26）、《关于增加回购股份资金来 源的公告》（公告编号：2025-27）。 根据《公司回购股份报告书》（公告编号：2025-06），若公司在本次回购 期限内发生派发红利、送红股、资本公积金转增股本等除权除息事项，自股价除 权除息之日起，按照中国证监会及深圳证券交易所的相关规定相应调整回购价格 上限。公司2024年度分红派息实施后，回购股份的价格上限由22元/股（含）调 整为21.65元/股（含），调整后的回购股份价格上限自2025年5月22日（除权除 息日）起生效。 证券代码：000739 证券简称：普洛药业 公告编号：2025-37 普洛药业股份有限公司 关于回购公司股份的进展 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：000739 证券简称：普洛药业 公告编号：2025-35 普洛药业股份有限公司 3、规格：15kg/桶 4、生产企业：浙江普洛康裕制药有限公司 5、通知书编号：2025YS00506 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。 二、药品其他相关情况 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局（以下简称"药监局"）签发的甲苯磺 酸多纳非尼《化学原料药上市申请批准通知书》。现将有关情况公告如下： 一、药品注册批准情况 1、化学原料药名称：甲苯磺酸多纳非尼 2、申请事项：境内生产化学原料药上市申请 甲苯磺酸多纳非尼片（商品名：泽普生/Zepsun）是药监局批准上市的Ⅰ类 创新药，上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司 （以下简称"泽璟制药"）；用于治疗既往未接受过全身系统性治疗的不可切除 肝细胞癌，以及进展性、局部晚期 ...

Core Viewpoint - Pro Pharmaceutical (000739) announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., received the approval notice for the listing application of Tofacitinib Tosylate from the National Medical Products Administration. This innovative Class I drug is intended for the treatment of unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer. The approval is expected to have a positive impact on the company's future operations [1]. Group 1 - The drug Tofacitinib Tosylate is classified as an innovative Class I drug [1]. - The drug is specifically used for treating unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer [1]. - The company has signed a research and production service contract with its partner, Suzhou Zejing Biopharmaceutical Co., Ltd., with the raw material ownership belonging to Zejing [1]. Group 2 - The approval from the National Medical Products Administration is anticipated to positively influence the company's future business operations [1].